| Purpose:To evaluate the effectiveness and safety of the dexamethasone intravitreal implant(DEX-I)in Non-Infectious Uveitis(NIU)in Chinese patients.Methods:Ninety-one eyes of 77 patients(56 men,21 women)receiving 130 implant injections for NIU were included.Treatment indication,uveitis diagnosis,best-corrected visual acuity(BCVA),central retinal thickness(CRT),vitreous haze score,intraocular pressure,phakic status,number of injections,time to reinjection,and systemic treatments were collected at baseline,1 week,1 month,3 and 6 months after treatment.Results:All patients were followed for at least 12 weeks and had a mean follow-up period of 5.1 months(range,3–14 months)after the first implant.The main treatment indications were macular edema(ME),retinal vasculitis,retinal vasculitis with ME.Sixty-one eyes(67.03%)received only one injection,while 31 eyes(32.97%)received two or more.In eyes that received 2 injections,the mean time to the second injection was 3.83 months and in those that received 3 injections,the mean time to the third injection was 7.5 months.BCVA and CRT significantly improved at 1 week,1month,3 months,and 6 months after treatment.When compared to baseline,the mean prednisone(or equivalent)dosage significantly decreased at 3-and 6-month follow-up evaluations after DEX implantation.14.29% of eyes developed a transient increase in intraocular pressure,and a cataract was removed from 1 phakic eye.Conclusion:DEX implants,either alone or in combination with common adjunctive NIU treatments,is safe and effective in the treatment of NIU in Chinese patients. |
PDF Full Text Request